This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01178/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01178/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/mixture/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01178/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01178/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01178/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01178/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01178/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/sukl/drug/
n13http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01178/identifier/wikipedia/

Statements

Subject Item
n2:DB01178
rdf:type
n3:Drug
n3:description
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. [PubChem]
n3:generalReferences
# Wollina U, Hipler UC, Seeling A, Oelschlager H: Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro. Skin Pharmacol Physiol. 2005 May-Jun;18(3):132-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15897685 # Seeling A, Oelschlager H, Rothley D: [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone] Pharmazie. 2000 Apr;55(4):293-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10798243 # Oelschlager H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, Machts H, Riederer H, Rackur H: [Cleavage and biotransformation of the central muscle relaxant chlormezanone] Pharmazie. 1998 Sep;53(9):620-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9770210 # Gautier V, Vincon G, Demotes-Mainard F, Albin H: [Pharmacokinetics of chlormezanone in healthy volunteers] Therapie. 1990 Jul-Aug;45(4):315-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2399514
n3:group
approved withdrawn
n3:indication
Used in the management of anxiety and in the treatment of muscle spasm.
owl:sameAs
n8:DB01178 n11:DB01178
dcterms:title
Chlormezanone
adms:identifier
n10:Chlormezanone n15:46505352 n16:PA448939 n17:2717 n18:DB01178 n19:D00268 n20:3619 n22:2616
n3:mechanismOfAction
Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
n3:synonym
Chlormethazanone Chlormezanona 2-(P-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide (+-)-Chlormezanone Chlormezanonum (±)-chlormezanone Chlormezanone Clormezanona 2-(P-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide
n3:toxicity
Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
n3:mixture
n14:271B4F6E-363D-11E5-9242-09173F13E4C5
n5:hasConcept
n6:M0004158
n3:IUPAC-Name
n4:271B4F73-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4F79-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4F78-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4F75-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4F76-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4F77-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4F89-363D-11E5-9242-09173F13E4C5 n4:271B4F71-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4F72-363D-11E5-9242-09173F13E4C5 n4:271B4F8B-363D-11E5-9242-09173F13E4C5 n4:271B4F6F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4F70-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:M03BB02
n3:H-Bond-Acceptor-Count
n4:271B4F7F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4F80-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4F7A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4F7B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4F7D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4F7C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4F7E-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
80-77-3
n3:category
n3:Bioavailability
n4:271B4F85-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4F87-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4F88-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4F8A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4F84-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4F83-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4F86-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4F74-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4F81-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4F82-363D-11E5-9242-09173F13E4C5